Mecasermin

Mecasermin
Clinical data
AHFS/Drugs.com monograph
Pregnancy cat. C(US)
Legal status ℞-only (US)
Routes Subcutaneous
Identifiers
ATC code H01AC03
UNII 7GR9I2683O Y
KEGG D04870 N
ChEMBL CHEMBL1201716 N
Chemical data
Formula  ?
 N(what is this?)  (verify)

Mecasermin (INN, brand name Increlex) is recombinant human insulin-like growth factor 1 (IGF-I) which is used for the long-term treatment of growth failure in children with severe primary IGF-I deficiency.[1][2]

This drug is not to be confused with mecasermin rinfabate (trade name: Iplex), which is the binary complex of recombinant human IGF-1 (rhIGF-1) and the binding protein that IGF-1 is naturally adhered to in the human body.

References

  1. ^ Fintini, D; Brufani, C; Cappa, M (2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and clinical risk management 5 (3): 553–9. PMC 2724186. PMID 19707272. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2724186. 
  2. ^ "Increlex". Drugs.com. http://www.drugs.com/increlex.html. Retrieved 10 January 2010. 
Hypothalamic
Agonists: Lanreotide • Octreotide • Pasireotide
Anterior pituitary
Agonists: IGF-1 (Mecasermin/Mecasermin rinfabate) • Sermorelin • Somatrem
Antagonists: Pegvisomant
Agonists: Thyrotropin
Posterior pituitary
Agonists: Carbetocin • Demoxytocin
Antagonists: Atosiban

M: END

anat/phys/devp/horm

noco(d)/cong/tumr, sysi/epon

proc, drug (A10/H1/H2/H3/H5)